Am J Transplant, Volume 21, Suppl 3 Archives - Page 114 of 139 - ATC Abstracts

2021 American Transplant Congress
Influence of HLA Compatibility on Bk Virus Associated Nephropathy Among Japanese Living Donor Kidney Transplant Recipients
N. Fujiyama¹, M. Saito², R. Yamamoto², R. Sagehashi², T. Saito², S. Kashima², K. Numakura², S. Narita², T. Habuchi², S. Satoh¹
¹Center for Kidney Disease and Transplantaion, Akita University Hospital, Akita, Japan, ²Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
*Purpose: BK polyomavirus-associated nephropathy (BKVN) after kidney transplantation is associated with a high morbidity and higher risk of graft loss. In this study, the relationship…
2021 American Transplant Congress
Titer Stability vs. Terminal Pre-transplant Titer: Titer History is Irrelevant for A₂ to B Transplantation
A. Gilbert¹, S. Radomski², J. Vucci¹, B. Thomas¹, M. Cooper¹
¹Medstar Georgetown Transplant Institute, Washington, DC, ²Johns Hopkins Medical Center, Baltimore, MD
*Purpose: Minor ABO incompatibile (ABOi) transplants from blood group A2 or A2B donors have increased since 2014, but initial guidance suggested that establishing an anti-A…
2021 American Transplant Congress
Findings from the BARETO Study: A New, Composite Renal Vascular Plaque Score is Highly Associated with Kidney Graft Survival
J. Foutz¹, D. Stewart¹, L. Kamal², H. McGehee¹, P. Saravanane², S. Yu², R. Yousfi², G. Gupta²
¹United Network for Organ Sharing, Richmond, VA, ²Virginia Commonwealth University School of Medicine, Richmond, VA
*Purpose: Whether anatomic findings such as aortic and arterial renal plaque affect kidney graft outcomes is not well defined. Other than anatomical damage, it is…
2021 American Transplant Congress
An Investigation of Surgeon’s Effect on Deceased-Donor Kidney Offers and Transplant Outcomes
A. C. Randa, J. P. Roberts
Department of Surgery, UCSF, San Francisco, CA
*Purpose: We studied the transplant surgeons' effect on accepting or rejecting the deceased donor kidney offers and their subsequent effect on transplant outcomes.*Methods: There are…
2021 American Transplant Congress
Experiential Expertise: What Can Patients and Donors Teach Us About Living Donation?
L. A. Davis¹, E. H. Wood², E. Ho³, R. Pines⁴, S. M. Advani⁵, A. D. Waterman²
¹DeSales University, Center Valley, PA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Terasaki Institute, Los Angeles, CA, ⁴Santa Barbara Cottage Hospital, Santa Barbara, CA, ⁵National Human Genome Research Institute, NIH, Bethesda, MD
*Purpose: While educational materials and discussions with medical professionals are factually sound, insight from actual living donors (LDs) and recipients (Rs) may offer unique, experiential…
2021 American Transplant Congress
Kidney Transplant Survival After Borderline Rejection in the Setting of Denovo Dsa Formation
A. P. Bregman¹, S. Jackson², S. Riad¹
¹Department of Nephrology, University of Minnesota, Minneapolis, MN, ²Biostatistics, M-Health Fairview Analytics, Minneapolis, MN
*Purpose: The significance of borderline cellular rejection has been questioned in the past. Data on borderline rejection with deNovo DSA (dnDSA) formation is limited. We…
2021 American Transplant Congress
Kidney Transplantation in Patients with Severe Pulmonary Hypertension: Not an Absolute Contraindication?
B. Prajapati¹, D. Gumber², I. Moinuddin¹, C. Bhati¹, G. Gupta¹, D. Grinnan³, D. Kumar¹
¹Nephrology, Virginia Commonwealth University, Richmond, VA, ²Cardiology, Virginia Commonwealth University, Richmond, VA, ³Pulmonology, Virginia Commonwealth University, Richmond, VA
*Purpose: Severe pulmonary arterial hypertension (PAH) as defined by a pulmonary artery systolic pressure (PASP) >50mmHg is associated with high peri-operative mortality and thus is…
2021 American Transplant Congress
A Comparative Analysis of Kidney Allograft Outcomes in Steroid Use versus Steroid Discontinuation After Basiliximab Induction: Unos Data Base Study
F. Cardarelli, H. Patel, A. Aala
Nephrology, BIDMC, Boston, MA
*Purpose: Basiliximab is a monoclonal antibody produced by recombinant DNA technology used by many transplant centers in the U.S. as induction immunosuppression. When Basiliximab is…
2021 American Transplant Congress
Early Conversion to Belatacept-based Therapy Improves Graft Function in Renal Transplant Patients
N. Huang¹, C. J. Yang², I. Movileanu¹, R. H. Dvorai³, K. M. Ecal¹, R. F. Saidi¹, A. N. Ayla Senay¹, B. Gallay⁴, M. J. Hanlon¹, S. Narsipur⁴, M. R. Laftavi¹, R. Shahbazov¹
¹Surgery, SUNY Upstate Medical University, Syracuse, NY, ²Pharmacy, SUNY Upstate Medical University, Syracuse, NY, ³Pathology, SUNY Upstate Medical University, Syracuse, NY, ⁴Medicine, SUNY Upstate Medical University, Syracuse, NY
*Purpose: Our goal in this study was to assess the impact of early vs late conversion to Belatacept based (Bela) IS in kidney transplant (KT)…
2021 American Transplant Congress
Creatinine Reduction Ratio at 2 Postoperative Day as a Predicting Factor of Long-Term Outcomes After Living Donor Kidney Transplantation
Y. Kinoshita, T. Shinzato, T. Shimizu, D. Iwami
Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
*Purpose: Creatinine reduction ratio from 1 to 2 postoperative days (CRR2) under 30% has been defined as a slow graft function (SGF) and used to…